Provided by Tiger Fintech (Singapore) Pte. Ltd.

Arbutus Biopharma

3.30
-0.0200-0.60%
Post-market: 3.300.00000.00%19:41 EDT
Volume:707.42K
Turnover:2.36M
Market Cap:625.32M
PE:-7.74
High:3.41
Open:3.34
Low:3.29
Close:3.32
Loading ...

Company Profile

Company Name:
Arbutus Biopharma
Exchange:
NASDAQ
Establishment Date:
- -
Employees:
73
Office Location:
701 Veterans Circle,Warminster,Pennsylvania,United States
Zip Code:
18974
Fax:
- -
Introduction:
Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-161, an oral HBV RNA destabilizer; AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Vaccitech plc to evaluate AB-729. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.

Directors

Name
Position
Mark J. Murray
President and Chief Executive Officer, and Director
Vivek Ramaswamy
Chairman of the Board
William T. Symonds
Chief Development Officer and Director
Daniel Burgess
Director
Frank Karbe
Director
Herbert J. Conrad
Director
Keith Manchester
Director
Richard Henriques
Director

Shareholders

Name
Position
Mark J. Murray
President and Chief Executive Officer, and Director
Bruce Cousins
Executive Vice President and Chief Financial Officer
Elizabeth Howard
Executive Vice President and General Counsel
Michael Sofia
Chief Scientific Officer
Peter Lutwyche
Chief Technology Officer
William T. Symonds
Chief Development Officer and Director